Jasper Therapeutics, Inc. 8-K

What Happened
Jasper Therapeutics, Inc. (JSPR) filed an 8-K reporting that director Christian Nolet informed the board he resigned from the Board and its committees effective May 15, 2026. The filing states Mr. Nolet’s resignation was not due to any disagreement with the company’s operations, policies or practices. The Board has appointed Svetlana Lucas, Ph.D., as a member of the Board’s Audit Committee.

Key Details

• Resignation notice date and effective date: May 15, 2026.
• Resignee: Christian Nolet — resigned from the Board and all Board committees.
• Audit Committee change: Svetlana Lucas, Ph.D. appointed as a member of the Audit Committee.
• Filing type: Form 8-K (no disagreement with management reported).

Why It Matters
Director and committee changes can affect governance and oversight — the Audit Committee role is important for financial reporting and controls. For investors, this filing signals a routine board personnel change (not related to a dispute). There were no reported disagreements with management and no other material financial information or transactions disclosed in this filing.